Education
About Us
Working with TipRanks
Follow Us
BioCryst Pharmaceuticals (BCRX)
NASDAQ:BCRX
BCRX Stock Chart & Stats
$6.76
-$0.02(-0.25%)
At close: 4:00 PM EST
$6.76
-$0.02(-0.25%)
Day’s Range― - ―
52-Week Range$6.00 - $11.31
Previous CloseN/A
Volume537.69K
Average Volume (3M)4.56M
Market Cap
$1.68B
Enterprise Value$2.02B
Total Cash (Recent Filing)$212.87M
Total Debt (Recent Filing)$683.11M
Price to Earnings (P/E)―
Beta0.78
Next Earnings
Feb 26, 2026EPS Estimate
0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.06
Shares Outstanding248,039,060
10 Day Avg. Volume4,044,907
30 Day Avg. Volume4,557,904
Financial Highlights & Ratios
PEG Ratio0.28
Price to Book (P/B)-3.27
Price to Sales (P/S)3.45
P/FCF Ratio-29.25
Enterprise Value/Market Cap1.21
Enterprise Value/Revenue3.37
Enterprise Value/Gross Profit3.46
Enterprise Value/Ebitda24.11
Forecast
1Y Price Target
$20.38Price Target Upside201.48% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Commercial Performance And Pediatric ExpansionOrladeyo sales beating expectations combined with approval of a pediatric granule formulation expands the addressable HAE population and supports broader prescribing activation across pediatric and adult clinicians.
Pipeline Diversification Into Orphan DiseaseBCX17725 targeting KLK5 for Netherton syndrome represents a meaningful diversification opportunity beyond hereditary angioedema that could create a new orphan-disease revenue stream if clinical data are favorable.
Strategic Acquisition Strengthening Product MixAcquisition of ATXS brings navenibart into the portfolio, adding an infrequently dosed plasma kallikrein antibody that could reinforce leadership in hereditary angioedema and complement the oral therapy franchise.
Bears Say
Competitive And Peak-sales UncertaintyInvestor worries about competition and disputed peak sales expectations for Orladeyo and navenibart have pressured the stock and could cap upside if market share assumptions are challenged.
Market Access And Diagnostic Hurdles For New IndicationsChallenges diagnosing Netherton syndrome and feedback of muted demand for pediatric prophylactic therapy may slow uptake of new treatments and limit commercial adoption despite clinical promise.
Rising Costs And Financing ConcernsCosts related to the Astria acquisition are expected to raise operating expenses and the mix of cash, debt and equity financing introduces margin pressure and potential dilution risk for shareholders.
BioCryst News
BCRX FAQ
What was BioCryst Pharmaceuticals’s price range in the past 12 months?
BioCryst Pharmaceuticals lowest stock price was $6.00 and its highest was $11.31 in the past 12 months.
What is BioCryst Pharmaceuticals’s market cap?
BioCryst Pharmaceuticals’s market cap is $1.68B.
When is BioCryst Pharmaceuticals’s upcoming earnings report date?
BioCryst Pharmaceuticals’s upcoming earnings report date is Feb 26, 2026 which is in 9 days.
How were BioCryst Pharmaceuticals’s earnings last quarter?
BioCryst Pharmaceuticals released its earnings results on Nov 03, 2025. The company reported $0.06 earnings per share for the quarter, beating the consensus estimate of $0.04 by $0.02.
Is BioCryst Pharmaceuticals overvalued?
According to Wall Street analysts BioCryst Pharmaceuticals’s price is currently Undervalued.
Does BioCryst Pharmaceuticals pay dividends?
BioCryst Pharmaceuticals does not currently pay dividends.
What is BioCryst Pharmaceuticals’s EPS estimate?
BioCryst Pharmaceuticals’s EPS estimate is 0.05.
How many shares outstanding does BioCryst Pharmaceuticals have?
BioCryst Pharmaceuticals has 248,039,060 shares outstanding.
What happened to BioCryst Pharmaceuticals’s price movement after its last earnings report?
BioCryst Pharmaceuticals reported an EPS of $0.06 in its last earnings report, beating expectations of $0.04. Following the earnings report the stock price went down -6.284%.
Which hedge fund is a major shareholder of BioCryst Pharmaceuticals?
Currently, no hedge funds are holding shares in BCRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
BioCryst Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$20.38 (201.48% Upside)
$20.38 (201.48% Upside)
Blogger Sentiment
Bullish
BCRX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 7.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $367.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.2%
Last 30 Days ▼ 3.1%
Last 30 Days ▼ 3.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-23.35%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-9.13%
Trailing 12-Months
Company Description
BioCryst Pharmaceuticals
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
BCRX Company Deck
BCRX Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The call reflected a strong performance by BioCryst with significant revenue growth, successful financial maneuvers, and promising pipeline developments. However, there were some challenges, including enrollment delays and increased costs. Overall, the company's positive results and strategic decisions indicate a promising outlook.View all BCRX earnings summariesBCRX Stock 12 Month Forecast
Average Price Target
$20.38
▲(201.48% Upside)
Technical Analysis
Ownership Overview
1.57% Insiders
14.78% Mutual Funds
3.88% Other Institutional Investors
63.56% Public Companies and Individual Investors